Neuroleptic Malignant Syndrome: A Case Treated With Bromocriptine

Case Reports ÖZET Nöreleptik malign sendrom: Bromokriptin ile tedavi edilen bir olgu Nöroleptik malign sendrom (NMS), özellikle antipsikotik tedavi esnasında nadir olarak görülen ve potansiyel olarak ölümcül olan bir sendromdur. Bu yazıda, hastanede uzun süredir tedavi altında bulunan, uzun yıllar-dır antipsikotik kullanımı ve birçok kez yatışları olan, şizoaffektif bozukluk tanısıyla izlenen bir olguda, oral ve depo antipsikotik kullanırken, oral antipsikotik ilaç tedavisinde yapılan doz artırımının ardından gelişen NMS ve ona yönelik tedavi yaklaşımı sunularak NMS tedavisinde bromokriptinin kullanımı tartışılmıştır. Anahtar kelimeler: Nöroleptik malign sendrom, antipsikotikler, bromokriptin ABSTRACT Neuroleptic malignant syndrome: a case treated with bromocriptine Neuroleptic malignant syndrome (NMS) is a potentially fatal syndrome which is rarely seen during treatment with antipsychotic medications. In this paper, the treatment of NMS that developed after a dose increase in oral antipsychotic drug therapy with depot antipsychotics in a patient with schizoaffective disorder, who has used antipsychotic medications for a long time and was hospitalized many times was reported and the treatment approach and bromocriptine use in NMS was discussed

Localized cutaneous leishmaniasis in a Turkish child

alper, murat/0000-0001-7069-0623WOS: 000172769000011PubMed: 11560166

ARTICLE IN PRESS Turkish Journal of Psychiatry 2011 of Turkey Ministry of Health, Bakirkoy Prof Dr. Mazhar Osman Training and Research Hospital for Mental Health and Neurological Diseases

SUMMARY Objective: The aim of this study is to examine the population targeted by the violent behavior of psychotic patients and to provide data on the treatment and therapeutic support of psychiatric professionals based on our results. Method: Eighty-one psychotic patients lacking criminal responsibility and under observation or mandatory treatment due to violent crime were compared with a control group of 31 persons with criminal responsibility. The sociodemographic features of the two groups' victims and descriptive data about the crimes and the target populations were examined and analyzed with SPSS 11. Results: Patient and control groups were compared according to their relationships to their victims. Of psychotic patients' victims, 36.9% percent were family members, while in the non-psychotic group the proportion was 10%, a statistically significant difference (p<0.01). We also found a statistically significant difference between the two groups in the mean ages of their victims and in the proportions who victimized married people, had previously met with their victims or who lived with their victims prior to the homicidal act. Conclusion: This study concludes that violent psychotic patients mostly choose their victims from among their family members. Psychotic patients were three times more likely to choose a relative compared to the control group. Recognizing the risk factors and the population most often targeted by homicidal behavior is essential for protecting patients and the community

Prevalence of depressive symptoms in elderly cancer patients receiving chemotherapy and influencing factors

BackgroundDepression is one of the most prevalent causes of distress in the geriatric population. The purpose of this study was to examine the prevalence of depressive symptoms in elderly cancer patients and to determine the possible associated factors

Comparison of clinical and laboratory features and treatment options of 237 symptomatic and asymptomatic children infected with SARS-CoV-2 in the early phase of the COVID-19 pandemic in Turkey

Since the first report of COVID-19 in December 2019, little is known about therapeutic usage of hydroxychloroquine in pediatric patients with COVID-19. We retrospectively retrieved data for SARS-CoV-2 PCR positive pediatric patients from 20 hospitals in 8 different cities in Turkey. We obtained patients' epidemiological, clinical, laboratory features and drugs used for treatment of COVID-19. 237 nasopharyngeal swab SARS-CoV-2 PCR positive children were included into the study from March 26 to June 20, 2020. The mean age of asymptomatic children (118±62 months) was found to be higher than that of symptomatic children (89±69 months). Symptomatic children had a significantly lower mean lymphocyte count and higher mean CRP, D-dimer value, procalcitonin and LDH than asymptomatic children in univariate analysis. Out of 156 children, 78 (50%) children received Hydroxychloroquine-containing regimen, 15 of them were treated with hydroxychloroquine + azithromycin + oseltamivir, 44 were treated with hydroxychloroquine + azithromycin and 21 were only treated with hydroxychloroquine. Among the 156 patients who received medical treatment, 90 (58%) patients had pre and/or post-treatment ECG performed upon them. However, none of them either reported ECG abnormalities or a need for discontinuation of hydroxychloroquine because of adverse drug reaction